Homepage Feature

Digital Replica Bill May Leave Performers Worse Off

Digital Replica Bill May Leave Performers Worse Off

The NO FAKES ACT may undermine performers’ control over their intellectual property rights.

The 2023 Regulatory Year in Review

The 2023 Regulatory Year in Review

The Regulatory Review presents our top essays from the past year.

The Next Generation of Regulatory Compliance

The Next Generation of Regulatory Compliance

A new book by a leading environmental regulator argues for creating rules that better facilitate industry compliance.

Cybersecurity Good Governance

Cybersecurity Good Governance

New SEC regulations are likely to change the cybersecurity landscape by encouraging more widespread adoption of best practices.

From Regulation 1.0 to 2.0

From Regulation 1.0 to 2.0

Technological changes are driving market changes that will call for new forms of regulation.

The Coast Guard’s Looming Challenges

The Coast Guard’s Looming Challenges

New maritime risks necessitate further strategic review of the Coast Guard’s legal authority and mission support capabilities.

California’s Attempt to Outlaw Caste-Based Discrimination

California’s Attempt to Outlaw Caste-Based Discrimination

Existing grounds of anti-discrimination law fail to protect vulnerable groups from bias on the basis of ancestry.

Use Specialized Juries in AI Litigation

Use Specialized Juries in AI Litigation

Increasingly complex AI cases require juries of experts and professional peers rather than a random selection of citizens.

Why “Big Data” Is a Big Deal

Why “Big Data” Is a Big Deal

The ongoing Google antitrust trial could shape the future role of big data in digital markets and artificial intelligence.

Let Us Not Raise a Ruckus Over Net Neutrality

Let Us Not Raise a Ruckus Over Net Neutrality

FCC Chair Rosenworcel should reconsider her messaging about the role of public comments in the new net neutrality proceeding.

The Fatal Flaws in the “Abortion Pill” Decision

The Fatal Flaws in the “Abortion Pill” Decision

By second-guessing FDA safety determinations, the Fifth Circuit challenges the Supreme Court to restore agency deference.

How Patents Contribute to High Drug Prices

How Patents Contribute to High Drug Prices

Patents covering drugs selected for Medicare price negotiation show how patents influence drug prices.